HansBiomed Corporation
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralize… Read more
HansBiomed Corporation (042520) - Total Assets
Latest total assets as of September 2025: ₩126.41 Billion KRW
Based on the latest financial reports, HansBiomed Corporation (042520) holds total assets worth ₩126.41 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
HansBiomed Corporation - Total Assets Trend (2012–2025)
This chart illustrates how HansBiomed Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
HansBiomed Corporation - Asset Composition Analysis
Current Asset Composition (September 2025)
HansBiomed Corporation's total assets of ₩126.41 Billion consist of 44.4% current assets and 55.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 6.5% |
| Accounts Receivable | ₩16.65 Billion | 13.2% |
| Inventory | ₩28.83 Billion | 22.8% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩535.75 Million | 0.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how HansBiomed Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HansBiomed Corporation's current assets represent 44.4% of total assets in 2025, an increase from 0.0% in 2012.
- Cash Position: Cash and equivalents constituted 6.5% of total assets in 2025, down from 8.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 22.8% of total assets.
HansBiomed Corporation Competitors by Total Assets
Key competitors of HansBiomed Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
JVM Co. Ltd
KQ:054950
|
Korea | ₩296.91 Billion |
HansBiomed Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - HansBiomed Corporation generates 0.71x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - HansBiomed Corporation is currently not profitable relative to its asset base.
HansBiomed Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.69 | 0.99 | 1.85 |
| Quick Ratio | 0.34 | 0.43 | 1.41 |
| Cash Ratio | 0.00 | 0.13 | 0.00 |
| Working Capital | ₩-24.96 Billion | ₩ -385.31 Million | ₩ 36.19 Billion |
HansBiomed Corporation - Advanced Valuation Insights
This section examines the relationship between HansBiomed Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.49 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.9% |
| Total Assets | ₩126.41 Billion |
| Market Capitalization | $246.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values HansBiomed Corporation's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: HansBiomed Corporation's assets grew by 3.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for HansBiomed Corporation (2012–2025)
The table below shows the annual total assets of HansBiomed Corporation from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | ₩126.41 Billion | +3.85% |
| 2024-09-30 | ₩121.72 Billion | -0.53% |
| 2023-09-30 | ₩122.37 Billion | -7.08% |
| 2022-09-30 | ₩131.69 Billion | +1.73% |
| 2021-09-30 | ₩129.44 Billion | -1.79% |
| 2020-09-30 | ₩131.81 Billion | -1.71% |
| 2019-09-30 | ₩134.09 Billion | +46.08% |
| 2018-09-30 | ₩91.80 Billion | +14.47% |
| 2017-09-30 | ₩80.19 Billion | +23.91% |
| 2016-09-30 | ₩64.72 Billion | +24.19% |
| 2015-09-30 | ₩52.11 Billion | +17.52% |
| 2014-09-30 | ₩44.34 Billion | +32.91% |
| 2013-09-30 | ₩33.36 Billion | +23.33% |
| 2012-09-30 | ₩27.05 Billion | -- |